Taysha Gene Therapies, Inc. TSHA Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s long-term debt?
- Taysha Gene Therapies, Inc. (TSHA) reported long-term debt of $48.96M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s long-term debt changed year-over-year?
- Taysha Gene Therapies, Inc.'s long-term debt increased by 15.3% year-over-year, from $42.45M to $48.96M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s long-term debt?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s long-term debt has grown at a 7.7% compound annual growth rate (CAGR), from $37.19M to $50.11M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.